TP53 and thyroid gland carcinoma: Moreover, five out of 12 (41%) DICER1-driven PDTC also had a TP53 mutation (4/12, 33%) or a TERT promoter mutation (1/12, 8%), alterations associated with progression of thyroid cancer (Figure 3A).